

Publikationsverzeichnis

1)

Originalarbeiten

1. Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji RM, Casper J, Edinger M, Zák P, Yakoub-Agha I, Ciceri F, Schroeder T, Zuckerman T, Kobbe G, Yeshurun M, Narni F, Finke J, Diez-Martin JL, Berceanu A, **Hilgendorf I**, Verbeek M, Olivieri A, Savani B, Spyridonidis A, Nagler A, Mohty M. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). *Bone Marrow Transplant.* doi: 10.1038/s41409-023-02028-x 2023, Online ahead of print.
2. Bug G, Labopin M, Niittyvuopio R, Stelljes M, Reinhardt HC, **Hilgendorf I**, Kröger N, Kaare A, Bethge W, Schäfer-Eckart K, Verbeek M, Mielke S, Carlson K, Bazarbachi A, Spyridonidis A, Savani BN, Nagler A, Mohty M. Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 58(6):710-716, 2023.
3. Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, Stauch T, Zamagni E, **Hilgendorf I**, Hochhaus A, Engelhardt M, von Lilienfeld-Toal M. Pomalidomide combinations are a safe and effective option after daratumumab failure. *J Cancer Res Clin Oncol.* 149(9):6569-6574, 2023
4. Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis JH, Grillo G, Salmenniemi U, **Hilgendorf I**, Kröger N, Poiré X, Cornelissen JJ, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M. Fludarabine versus cyclophosphamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Am J Haematol* 98(4):580-587, 2023
5. Frietsch JJ, Flossdorf S, Beck JF, Kröger N, Fleischhauer K, Dreger P, Schetelig J, Bornhäuser M, Hochhaus A, **Hilgendorf I**. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany. *Br J Haematol.* 201(2):308-318, 2023
6. Wittwer A, Sponholz K, Frietsch JJ, Linke P, Kropp P, Hochhaus A, **Hilgendorf I**. Psychosocial distress in young adults surviving hematological malignancies: a pilot study. *J Cancer Res Clin Oncol.* 149(9):5655-5663, 2023
7. Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, Berceanu A, Rambaldi A, Hilgendorf I, Kröger N, Mielke S, Zuckerman T, Sanz J, Busca A, Ozdogu H, Anagnostopoulos A, Savani B, Giebel S, Bazarbachi A, Spyridonidis A, Nagler A, Mohty M. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). *Bone Marrow Transplant.* 57, 1803-1809, 2022
8. Kunadt D, Stasik S, Metzeler KH, Röllig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Scholl S, **Hilgendorf I**, Brümmendorf TH, Jost E, Steffen B, Bug G, Einsele H, Görlich D, Sauerland C, Schäfer-Eckart K, Krause SW, Hänel M, Hanoun M, Kaufmann M, Wörmann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Müller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhäuser M, Middeke JM, Stölzel F; A. M. L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL). Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. *J Hematol Oncol.* 15(1):126. 2022, doi./10.1186/s13045-022-01339-8
9. Brioli A, Nögler TM, Yomade O, Rührich MM, Scholl S, Frietsch JJ, Hilgendorf I, Ernst T, Sayer HG, Hochhaus A, Mügge LO, von Lilienfeld-Toal M. Sex-disaggregated analysis of biology, treatment tolerability and outcome of Multiple Myeloma in a German cohort. *Oncol Res Treat.* 45(9):494-503, 2022
10. Beelen DW, Stelljes M, Reményi P, Wagner-Drouet EM, Dreger P, Bethge W, Ciceri F, Stölzel F, Junghanß C, Labussiere-Wallet H, Schaefer-Eckart K, Grigoleit GU, Scheid C, Patriarca F, Rambaldi A, Niederwieser D, **Hilgendorf I**, Russo D, Socié G, Holler E, Glass B, Casper J, Wulf G, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, La Rocca U, Finke J, Benedetti F, Pichlmeier U, Klein A, Baumgart J, Markiewicz M. Treosulfan compared with reduced-intensity busulfan improves allogeneic

- hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. *Am J Hematol.* 2022 Aug;97(8):1023-1034.
11. Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, **Hilgendorf I**, Hunter H, Nicholson E, Bloor A, Snowden JA, Verbeek M, Clark A, Savani BN, Spyridonidis A, Nagler A, Mohty M. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. *Bone Marrow Transplant.* 57(8), 1269-1276, 2022 May 14.
 12. Frietsch JJ, Miethke J, Linke P, Crodel CC, Schnetzke U, Scholl S, Hochhaus A, **Hilgendorf I**. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. *Bone Marrow Transplant.* 57(7):1164-1170, 2022
 13. Schaffrath J, Brummer C, Wolff D, Holtick U, Kröger N, Bornhäuser M, Kraus S, **Hilgendorf I**, Blau IW, Penack O, Wittke C, Steiner N, Nachbaur D, Thurner L, Hindah H, Zeiser R, Maier CP, Bethge W, Müller LP. High mortality of COVID-19 early after allogeneic stem cell transplantation - a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. *Transplant Cell Ther.* 28(6); 337e1-337e10, 2022
 14. Fleischmann M, Scholl S, Frietsch JJ, **Hilgendorf I**, Schrenk K, Hammersen J, Prims F, Thiede C, Hochhaus A, Schnetzke U. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. *J Cancer Res Clin Oncol.* 148, 3191-3202, 2022
 15. O'Hagan Henderson S, Frietsch JJ, **Hilgendorf I**, Hochhaus A, Köhne H, Casper J. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. *J Cancer Res Clin Oncol.* 148(10):2599-2609, 2022
 16. Mühleck R, Scholl S, **Hilgendorf I**, Schrenk K, Hammersen J, Frietsch JJ, Fleischmann M, Sayer HG, Hochhaus A, Schnetzke U. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. *J Cancer Res Clin Oncol.* 148, 2539-48, 2022
 17. Fleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J, Glaser A, **Hilgendorf I**, Hochhaus A, Scholl S. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. *J Cancer Res Clin Oncol.* 148, 1481-1492, 2022
 18. Eyre TA, Caillard S, Finel H, Boumendil A, Kothari J, Zimmermann H, Trappe RU, De Wilde V, Tholouli E, Kanfer E, Broom A, Damaj G, Bargetzi M, Kozák T, **Hilgendorf I**, Crawley C, Kerre T, Trněný M, Bachy E, Robinson S, Montoto S. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. *Bone Marrow Transplant* 6(9):2118-2124, 2021
 19. Toenges R, Greinix H, Lawitschka A, Halter J, Baumgartner A, Simon A, Arends J, Jäger P, Middeke M, **Hilgendorf I**, Klein S, Wagner-Drouet EM, Schmid C, Bug G, Wolff D, On behalf of the German-Austrian-Swiss GvHD Consortium. Current practice in nutrition after allogeneic hematopoietic stem cell transplantation - Results from a survey among hematopoietic stem cell transplant centers. *Clinical Nutrition* 40:1571-77, 2021
 20. Wagner-Drouet E, Teschner D, Wolschke C, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, **Hilgendorf I**, Klein S, Verbeek M, Ditschkowski M, Koch M, Lindemann M, Schmidt T, Rasche A, Barabas S, Deml L, Wagner R, Wolff D. Comparison of Cytomegalovirus-specific immune cell response to proteins versus peptides using an IFN- γ ELISpot assay after hematopoietic stem cell transplantation. *Diagnostics* 11(2):312. 2021
 21. **Hilgendorf I**, Bergelt C, Bokemeyer C, Kaatsch P, Seifart U, Stein A, Langer T. Long-term follow-up of children, adolescents and young adult cancer survivors. *Oncol. Res. Treat.* 44(4):184-189. 2021
 22. Brioli A, vom Hofe F, Rucci P, Ernst T, Yomade O, **Hilgendorf I**, Scholl S, Sayer H, Mügge LO, Hochhaus A, von Lilienfeld-Toal M. Melphalan 200 mg/m² improves survival without increased toxicity in comparison to reduced doses of Melphalan in multiple myeloma patients. *Bone Marrow Transplant,* 56(5):1209-1212. 2021
 23. Pulewka K, Strauss B, Hochhaus A, **Hilgendorf I**. Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. *J Cancer Res Clin Oncol.* 147:1239-1246. 2021
 24. Frietsch JJ, Hunstig F, Wittke C, Junghanss C, Franiel T, Scholl S, Hochhaus A, **Hilgendorf I**. Extramedullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. *Bone Marrow Transplant* 56(1):101-109. 2021

25. Wolff D, Herzberg PY, Herrmann A, Pavletic SZ, Heussner P, Mumm F, Höfer C, **Hilgendorf I**, Hemmati PG, Holler E, Greinix H, Mitchell SA. Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. *BMT* 56(1):243-256. 2021
26. Rachow T, Lamik T, Kalkreuth J, Kurze S, Wagner K, Stier P, Hammersen FJ, Rührich MM, Winkelmann N, Klink A, **Hilgendorf I**, Hermann B, Lang S, Hochhaus A, von Lilienfeld-Toal M. Detection of community-acquired respiratory viruses in allogeneic stem-cell transplant recipients and controls-A prospective cohort study. *Transpl Infect Dis.* 22:e13415. 2020.
Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, **Hilgendorf I**, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rasche A, Guldan H, Barabas S, Deml L, Wagner R, Wolff D. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. *Haematologica.* 106(2):363-374, 2021
27. Beelen DW, Trenschele R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, **Hilgendorf I**, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. *Lancet Haematol.* 7(1): e28-e39. 2019
28. Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, **Hilgendorf I**, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A. Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors – presentation of the CARE for CAYA-Program study protocol and associated literature review Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors – presentation of the CARE for CAYA-Program study protocol and associated literature review. *BMC Cancer.* 20(1):16. 2020
29. Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, **Hilgendorf I**, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M. Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation. *Blood* 134(11):892-899. 2019
30. Lamby P, Wolff D, Mielke S, Grigoleit GU, Ljungman P, **Hilgendorf I**, Holler E, Holler B, Weber D, Herr W, Schiltz D, Klein S, Graf S, Bjornhagen-Safwenberg V, Dolderer J, Prantl L. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation – a retrospective analysis on 7 patients. *Ann Hematol* 98(8):1867-1875.2019
31. Wolff D, **Hilgendorf I**, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H. Changes in immunosuppressive treatment of chronic graft-versus-host disease - comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centers in Germany, Austria and Switzerland. *Biol Blood Marrow Transplant.* 25(7):1450-1455. 2019
32. Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, **Hilgendorf I**, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO, von Lilienfeld-Toal M. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. *Ann Hematol.* 98(3):713-722. 2019
33. Wang L, Ni M, Hüchelhoven-Krauss A, Sellner L, Hoffmann JM, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen B, Wuchter P, Eckstein V, Krüger W, **Hilgendorf I**, Yerushalmi R, Nagler A, Müller-Tidow C, Ho AD, Dreger P, Schmitt M, Schmitt A. Modulation of B Cells and Homing Marker on NK Cells through Extracorporeal Photopheresis in Patients with Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. *Front Immunol.* 9: 1-15. 2018

34. Kühl R, Meier S, Baeurle M, Wolff D, Lawitschka A, Halter J, Bertz H, **Hilgendorf I**. Sport- und physiotherapeutische Maßnahmen zur Behandlung der chronischen Graft-versus-Host-Krankheit. *Phys Med Rehab Kuror.* 28(04): 224-230. 2018
35. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, **Hilgendorf I**, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nat Med.* 24(3):282-291.2018. Erratum in *Nat Med.* 24(4):526.2018.
36. Schumacher H, Stüwe S, Kropp P, Diedrich D, Freitag S, Greger N, Junghanss C, Freund M, **Hilgendorf I**. A prospective, randomized evaluation of the feasibility of exergaming on patients undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 53(5):584-90. 2018
37. van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, **Hilgendorf I**, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. *Bone Marrow Transplant.* 53(3):255-263.2018.
38. Pulewka K, Wolff D, Herzberg PY, Greinix H, Heussner P, Mumm FHA, von Harsdorf S, Rieger K, Hemmati P, Hochhaus A, **Hilgendorf I**. Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. *J Cancer Res Clin Oncol.* 143(8):1613-1619. 2017.
Hilgendorf I, Greinix H, Halter J, Lawitschka A, Wolff D. Vaccination of allogeneic hematopoietic stem cell transplant recipients-what should be considered? *Ann Hematol.* 96(4):701-702. 2017.
39. Fischer M, Schnetzke U, Spies-Weissart B, Walther M, Fleischmann M, **Hilgendorf I**, Hochhaus A, Scholl S. Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. *Haematologica.* 102(4):e129-e131. 2017.
40. Fleischmann M, Schnetzke U, Schrenk KG, Schmidt V, Sayer HG, **Hilgendorf I**, Hochhaus A, Scholl S. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. *J Cancer Res Clin Oncol.* 143(2):337-345. 2017
41. Winkelmann N, Desole M, **Hilgendorf I**, Ernst T, Sayer HG, Kunert C, Mügge LO, Hochhaus A, Scholl S. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. *J Cancer Res Clin Oncol.* 142(12):2603-2610. 2016.
39. Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, **Hilgendorf I**, Hirt C, Ho AD, Freund M, Schmitt M. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation. *Int J Cancer.* 138(7):1792-801. 2016.
40. Hautmann AH, Wolff D, **Hilgendorf I**, Fehn U, Edinger M, Hoffmann P, Herr W, Kölbl O, Holler B, Sporrer D, Holler E, Hautmann MG. Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. *Radiother Oncol.* 116(2):287-93. 2015.
41. Richter D, Koehler M, Friedrich M, **Hilgendorf I**, Mehnert A, Weißflog G. Psychosocial interventions for adolescents and young adult cancer patients: A systematic review and meta-analysis. *Crit Rev Oncol Hematol.* 95(3):370-86. 2015.
42. Geue K, Schmidt R, Nielsen T, **Hilgendorf I**, Kropp P, Richter D, Sender A, Friedrich M, Brähler E, Stöbel-Richter Y. The extension of the Leipzig questionnaire of motives to have a

- child (LKM) for use in oncology--test construction and psychometric review. *Psychother Psychosom Med Psychol.* 65(3-4):119-25. 2015.
43. Lorenz K, Rommel K, Mani J, Jin N, **Hilgendorf I**, Ho AD, Freund M, Schmitt M, Schmitt A. Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute GvHD or graft rejection. *Leuk Lymphoma.* 56:671-5. 2015.
 44. Schmitt M, Trenscher R, Sayer HG, Schneider C, Glass A, **Hilgendorf I**, Treschl A, Junghanss C, Borchert K, Koenigsmann M, Casper J, Beelen DW, Freund M, Kahl C. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. *Mol Clin Oncol.* 2(5):773-782. 2014
 45. Müller B, Baum A, Holzhausen M, Grittner U, **Hilgendorf I**, Martus P, Altiner A, Evers S, Rolfs A, Zettl UK, Kropp P. [The Rostock Headache Questionnaire ("Rokoko")--validation of a tool to screen and to qualify primary headaches]. *Fortschr Neurol Psychiatr.* 2014; 82(3):145-8.
 46. Wolff D, Ayuk F, Elmaagacli A, Bertz H, Lawitschka A, Schleuning M, Meyer RG, Gerbitz A, **Hilgendorf I**, Hildebrandt GC, Edinger M, Klein S, Halter J, Mousset S, Holler E, Greinix HT. Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers. *Biol Blood Marrow Transplant.* 19(5):767-76. 2013.
 47. Schmitt M, Xu X, **Hilgendorf I**, Schneider C, Borchert K, Gläser D, Freund M, Schmitt A. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. *Bone Marrow Transplant.* 48(7):922-5. 2013
 48. Herzberg PY, Lee SJ, Heussner P, Mumm FHA, **Hilgendorf I**, von Harsdorf S, Hemmati P, Rieger K, Greinix HT, Freund M, Holler E, Wolff D. Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center. *Bone Marrow Transplant.* 48(1):129-34. 2013
 49. Kramer M, Heussner P, Herzberg PY, Andree H, **Hilgendorf I**, Leithaeuser M, Junghanss C, Freund M, Wolff D. Validation of the grip test and human activity profile for evaluation of physical performance during the intermediate phase after allogeneic hematopoietic stem cell transplantation. *Support Care Cancer.* 21(4):1121-9. 2013.
 50. **Hilgendorf I**, Wolff D, Nogai A, Kundt G, Hahn J, Holler E, Uharek L, Junghanss C, Leithäuser M, Thiel E, Freund M, Kahl C. Chronic Graft versus Host Disease but not the Intensity of Conditioning has Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Hematological Diseases. *Onkologie.* 35(9):487-92. 2012
 51. Casalegno-Garduño R, Meier C, Schmitt A, Spitschak A, **Hilgendorf I**, Rohde S, Hirt C, Freund M, Pützer BM, Schmitt M. Immune Responses to RHAMM in Patients with Acute Myeloid Leukemia after Chemotherapy and Allogeneic Stem Cell Transplantation. *Clin Dev Immunol.* 2012: ID:146463. doi:10.1155/2012/146463
 52. Kropp P, Brecht IB, Niederberger U, Kowalski J, Schröder D, Thome J, Meyer W, Wallasch TM, **Hilgendorf I**, Gerber WD. Time-dependent post-imperative negative variation indicates adaptation and problem solving in migraine patients. *J Neural Transm.* 119(10):1213-21, 2012.
 53. Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W, Illmer T, Reichmann H, Ziemssen T, Siepmann T, Schwarzer A, Schwittay M, Stiegler R, Hurtz HJ, Schwerdtfeger T, Schwarz M, Dachsel R, Domke S, Kühn G, Mohr B, **Hilgendorf I**, et al. Immunoglobulins in PID, SID and neurological autoimmune disease. *Dtsch Med Wochenschr.* 137(13):675-80, 2012.
 54. **Hilgendorf I**, Mueller-Hilke B, Kundt G, Holler E, Hoffmann P, Edinger M, Freund M, Wolff D. The lack of memory B cells including T cell independent IgM(+) IgD(+) memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. *Transpl Int.* 25(1): 87-96, 2012.
 55. Löbermann M, Boršo D, **Hilgendorf I**, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. *Autoimmun Rev.* 11(3):212-8. 2012.
 56. **Hilgendorf I**, Freund M, Jilg W, Einsele H, Gea-Banacloche J, Greinix H, Halter J, Lawitschka A, Wolff D, Meisel R. Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. *Vaccine.* 29(16):2825-33, 2011.
 57. **Hilgendorf I**, Loebermann M, Borchert K, Junghanss C, Freund M, Schmitt M. Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. *Bone Marrow Transplant.* 46(9):1274-5. 2011

58. Kahl C, Hirt C, Decker S, Gläser D, Rohde S, Jost K, **Hilgendorf I**, Respondek-Dryba E, Leithäuser M, Junghanss C, Freund M. Multimodal therapy for localized spinal epidural follicular lymphoma. *Onkologie*. 33(7):381-4. 2010.
59. **Hilgendorf I**, Wolff D, Gromke T, Trenscher R, Elmaagacli AH, Pichlmeier U, Junghanss C, Freund M, Beelen DW, Casper J. Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. *Bone Marrow Transplant*. 46(4):502-9, 2011.
60. Herzberg PY, Heussner P, Mumm FH, Horak M, **Hilgendorf I**, von Harsdorf S, Hemmati P, Rieger K, Greinix H, Freund M, Lee SJ, Holler E, Wolff D. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 16(12):1707-17, 2010
61. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. *J Clin Oncol*. 10;28(20):3344-51, 2010. Erratum in: *J Clin Oncol*. 28(23):3797, 2010
62. Landfried K, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D, Hilgendorf I, Hahn J, Edinger M, Hoffmann P, Obermeier F, Schoelmerich J, Andreesen R, Holler E. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. *Clin Exp Immunol*. 159(1):87-92, 2010
63. Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, Weirich V, **Hilgendorf I**, Storb R, Freund M, Junghanss C. Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. *Exp Hematol*. 37(1): 143-50, 2009
64. Holler E, Rogler G, Brenmoehl J, Hahn J, Greinix H, Dickinson AM, Socie G, Wolff D, Finke J, Fischer G, Jackson G, Rocha V, Hilgendorf I, Eissner G, Marienhagen J, Andreesen R. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. *Int J Immunogenet*. 35(4-5): 381-4, 2008
65. Kahl C, **Hilgendorf I**, Freund M, Casper J. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma. *Onkologie*, 31(8-9): 485, 2008
66. **Hilgendorf I**, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. *Ann Hematol*. 87(12): 1009-12, 2008
67. Andree H, **Hilgendorf I**, Leithaeuser M, Junghanss C, Holzhueter S, Loddenkemper C, Steiner B, Freund M, Wolff D. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. *Bone Marrow Transplant*. 42(8): 541-62, 2008
68. Wolff D, Andree H, Hilgendorf I, Casper J, Freund M, Junghanss C. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation--timing and conditioning regimen may be crucial. *Biol Blood Marrow Transplant*, 14(8): 942-3, 2008
69. Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. *Bone Marrow Transplant*. 38(6): 445-51, 2006
70. Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hahling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M. Allogene Blutstammzelltransplantation von Risikopatienten nach Treosulfan und Fludarabin. [Allogeneic blood stem cell transplantation of high-risk patients after conditioning with treosulfan and fludarabine]. *Dtsch.Med Wochenschr*. 130: 2125-2129, 2005
71. Junghanss C, Waak M, Knopp A, Kleine H-D, Kundt G, Leithäuser M, Hilgendorff I, Wolff D, Casper J, Freund M. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression. *Neoplasma* 52: 402-410, 2005
72. **Hilgendorf I**, Weirich V, Zeng L, Koppitz E, Wegener R, Freund M, Junghanss C. Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. *Vet RES Commun* 29: 103-110, 2005
73. Jaster R, **Hilgendorf I**, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. *Biochem Pharmacol* 66: 633-641, 2003
74. Schuh A, Aßmuth K, **Hilgendorf I**, Müller PK, Kruse C. Translational activity of eucaryotic cells could be decreased by antisense-DNA of the multi KH domain protein vigilin. *Int J Mol Med* 12: 35-43, 2003.

75. **Hilgendorf I**, Van de Perck M, Emmrich J, Krammer HJ, Kruse C. Vigilin and pancreatic enzyme expression in isolated pancreatic acini after mellitin and gamma interferon treatment. *Pancreatology* 3: 336-341, 2003.
76. **Hilgendorf I**, Gellersen O, Emmrich J, Mikkat U, Rohwedel J, Krammer HJ, Müller PK, Kruse C. Estradiol has a direct impact of the exocrine pancreas as demonstrated by enzyme and vigilin expression. *Pancreatology* 1: 24-29. 2001.

Übersichtsarbeiten

77. Kröger N, Gagelmann N, **Hilgendorf I**. Allogene Stammzelltransplantation bei myeloproliferativen Erkrankungen. *Die Onkologie*. 29: 339-45.2023
78. Bergelt C, Bokemeyer C, **Hilgendorf I**, Langer T, Rick O, Seifart U, Koch-Gromus U. Langzeitüberleben bei Krebs: Definitionen, Konzepte und Gestaltungsprinzipien von Survivorship-Programmen. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 65(4):406-411. 2022
79. Laws HJ, Baumann U, Bogdan C, Burchard G, Christopeit M, Hecht J, Heining U, **Hilgendorf I**, Kern W, Kling K, Kobbe G, Külper W, Lehrnbecher T, Meisel R, Simon A, Ullmann A, de Wit M, Zepp F. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (Antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 63(5): 588-644. 2020
- Gebauer J, Hilgendorf I, Koch B-, Langer T. Neue Strukturen in der Betreuung und Nachsorge junger Krebspatienten. *Oncol Res Treat*. 42(suppl 3):21-26. 2019**
- Hilgendorf I**, Greinix H, Halter JP, Lawitschka A, Bertz H, Wolff D. Long-term follow up after allogeneic stem cell transplantation. *Dtsch Arztebl Int*. 112(4): 51-58. 2015
80. **Hilgendorf I**, Hochhaus A. Spätfolgen der allogenen Stammzelltransplantation. *Der Onkologe*, 21, 433-4242, 2015
81. **Hilgendorf I**, Wolff D. Treatment options for graft-versus-host disease. *Expert opinion on orphan drugs* 2013; 1(9), 731-43. 2013

Fallbeschreibungen

82. Appel TM, Stein C, Brandt C, Rödel J, Frietsch JJ, Miethke J, Hochhaus A, Hilgendorf I. Isolation of *Hafnia paralvei* co-harboring bla_{NDM-1} and bla_{VIM-1} in a woman who underwent allogeneic hematopoietic stem cell transplantation. *Infection*. 2023; 51(4):1161-1164.
83. O'Hagan Henderson S, Glaser A, Frietsch JJ, Hochhaus A, **Hilgendorf I**. The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. *Ann Hematol*. 101(4), 919-920, 2021
84. Voigt M, Sinn K, Malouhi A, Gecks T, Zinke J, **Hilgendorf I**, Scholl S, Hochhaus A, Schnetzke U. HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient. *Ann Hematol* 100(7):1895-1897. 2021
85. Ernst P, Engmann B, Frietsch JJ, Schnetzke U, Scholl S, Theis B, Kreipe HH, Ernst T, Glaser A, Haferlach T, Koch T, Hochhaus A, **Hilgendorf I**. A 19-year-old patient with atypical chronic myeloid leukemia. *Ann Hematol* 99(5):1145-1148. 2020
- Frietsch JJ, Michel D, Stamminger T, Hunstig F, Birndt S, Schnetzke U, Scholl S, Hochhaus A, **Hilgendorf I**. In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. *Mediterr J Hematol Infect Dis*. 2019 Jan 1;11(1):e2019001. doi: 10.4084/MJHID.2019.001.
86. Frietsch JJ, Winkelmann N, Hunstig F, Schnetzke U, Hammersen FJ, Dönicke T, Lenz M, Gras F, Scholl S, Hochhaus A, **Hilgendorf I**. A mosquito bite with devastating complications in an immunocompromised patient. *Case Rep Oncol* 12: 22–28. 2019.
87. Fleischmann T, **Hilgendorf I**, Franiel T. Das Myelosarkom der Hypophyse - eine Rarität eines isolierten Rezidivs einer akuten myeloischen Leukämie. *Röfo*. 190(3):273-74.2018.
88. Stubert J, **Hilgendorf I**, Stengel B, Krammer-Steiner B, Freund M, Gerber B. Bilateral breast enlargement and reddish skin macules as first signs of acute lymphoblastic T cell leukemia. *Onkologie*. 34(7):384-7, 2011.
89. Leithauser M, Kahl C, Aepinus C, Prall F, Maruschke M, Riemer H, Wolff D, Jost K, Hilgendorf I, Freund M, Junghans C. Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation. *Transpl Infect Dis*. 12(3):251-7, 2010.

90. Ruck S, Hilgendorf I, Müller-Hilke B, Kiefel V, Junghanss C, Freund M, Greinix H, Wolff D. Autoantibody-mediated agranulocytosis in association with chronic GVHD. *Bone Marrow Transplant.* 42(5): 359-60, 2008
91. Jost K, Leithäuser M, Grosse-Thie C, Bartolomaeus A, Hilgendorf I, Andree H, Casper J, Freund M, Junghanss C. Perforation of the superior vena cava - a rare complication of central venous catheters. *Onkologie*, 31(5): 262-4, 2008
92. **Hilgendorf I**, Aepinus C, Wolff D, Leithaeuser M, Junghanss C, Casper J, Freund M. Visual deterioration after gram-negative sepsis in neutropenia. *Ann Hematol* 87(2): 155-157, 2008
93. Hilgendorf I, Casper J, Sviland L, Prall F, Junghanss C, Freund M, Wolff D. Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplant.* 39(4): 245-6, 2007
94. **Hilgendorf I**, Wilhelm S, Prall F, Junghanss C, Steiner B, Wolff D, Freund M, Casper J. Headache after hematopoietic stem cell transplantation: being aware of chronic bilateral subdural hematoma. *Leuk Lymphoma.* 47(10): 2247-9, 2006
95. **Hilgendorf I**, Wolff D, Wilhelm S, Steiner B, Kiefel V, Hickstein H, Junghanss C, Freund M, Casper J. T-cell-depleted stem cell boost for the treatment of autoimmune haemolytic anaemia after T-cell-depleted allogeneic bone marrow transplantation complicated by adenovirus infection. *Bone Marrow Transplant.* 37(10): 977-978. 2006

Sonstige Publikationen

96. Maschmeyer G, Dittrich R, Fehm T, **Hilgendorf I**, Loibl S. Management onkologischer Erkrankungen in der Schwangerschaft. *FORUM*, 38, 16-21, 2022
97. Bergelt C, Bokemeyer C, **Hilgendorf I**, Koch-Gromus U, Langer T, Rick O, Seifart U. AG LONKO („Langzeitüberleben nach Krebs“) im Nationalen Krebsplan, Empfehlungspapier der Unterarbeitsgruppe „Bedarfsgerechte Versorgungsmodelle“, https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/N/Nationaler_Krebsplan/Empfehlungspapier_UAG_Versorgungsmodelle_AG_LONKO_bf.pdf
98. Arndt V, Hilgendorf I, Kaatsch P. AG LONKO („Langzeitüberleben nach Krebs“) im Nationalen Krebsplan, Empfehlungspapier der Unterarbeitsgruppe „Datenerhebung und Datenanalyse“, https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/N/Nationaler_Krebsplan/Empfehlungspapier_UAG_Daten_AG_LONKO_bf.pdf
99. Ayuk F, Bachmann B, Collier G, **Hilgendorf I**, Kalusche EM, Kiefer-Trendelenburg T, Krauth K, Kröger N, Lotze C, Lellek H, Mumm A, Orth HB, Schlegel PG, Schmitz J, Schwerdtfeger R, Steimann M, Stehr W, Stöcklein EM, Strohscheer I, Uhrig M. Stationäre Rehabilitation nach allogener Stammzelltransplantation – Rahmenempfehlungen zur Qualitätssicherung. *Tumor Diagnostik & Therapie* 2020; 41(10): 680 – 694
100. Koehler M, Mann J, Richter D, **Hilgendorf I**. Krebs bei Jugendlichen und jungen Erwachsenen Status quo der interdisziplinären Versorgung in Deutschland. *FORUM* 35, 37–42, 2020
101. Bokemeyer C, **Hilgendorf I**, Stein A. Forschungspriorität: Langzeitüberleben mit und nach Krebs. - „Roadmap 2019 für die Erforschung von Krebs- und Bluterkrankungen in Deutschland“ der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie, *GPSR15*, 12-13, 2019
102. **Hilgendorf I**. Langzeitfolgen und Nachsorge nach Blutstammzelltransplantation. *Spectrum Onkologie* 7: 32-34. 2018.
103. Quidde J, Koch B, Salchow J, Jensen W. von Gundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielack S, Calaminius G, Classen CF, Rössig C, Faber J, Faller H, **Hilgendorf I**, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Sander A, Köhler M, Stein A. Das CARE for CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung. *FORUM* 32: 479-484. 2017.
104. **Hilgendorf I**, Aßmuth K, Sparmann G, Emmrich J, Kruse C. Enhanced vigilin and anionic trypsinogen expression in experimental chronic pancreatitis. *CEJM*, 2(2); 159-167, 2007.
105. **Hilgendorf I**, Freund M, Kropp P, Hartmann S, Krogmann D, Daunke A, Klasen J, Klöcking S, Zettl H, Classen CF. Onkologische Erkrankungen bei Jugendlichen und jungen Erwachsenen – Zahlen aus dem klinischen Krebsregister Rostock als Arbeitsgrundlage für eine interdisziplinäre Herausforderung. *TumorDiagn u Ther* 32:85-92, 2011

2)

Buchbeiträge

1. **Hilgendorf I**, Christopeit M. Immunrekonstitution, Impfungen und Infektionen. In Ayuk S, Kröger NM, Ticelli A: Langzeitnachsorge von Patienten nach allogener Stammzelltransplantation. 1. Auflage 2018, Uni-Med Science, ISBN 978-3-8374-2387-7, Seite 45-56
2. **Hilgendorf I**, Wolff D. Transplantat-gegen-Wirt-Erkrankung (GVHD). In Miehle S, Madisch A: Topische Steroide in der Gastroenterologie, Uni-Med-Science
 1. Auflage 2013, ISBN 978-3-8374-1361-8 (deutschsprachig); ISBN 978-1-84815-199-4 (englischsprachig)
 2. neubearbeitete Auflage 2016; ISBN 978-3-8374-2375-4 (deutschsprachig), ISBN 978-3-8374-2383-9 (englischsprachig)
3. **Hilgendorf I**, Wolff D, Holler E: Klinische Praxis der akuten und chronischen GVHD. In Haas R und Kobbe G: Blutstammzelltransplantation – Bilanz des aktuellen Wissens. DUP Verlag 75-93, 2012, ISBN 978-3-940671-99-8